Short Reads

Premium

This section includes last week's Short Reads that were inadvertently omitted from last week's In Sequence.

Life Technologies Posts $107M Q4 Loss on Merger Charges

Life Technologies posted a fourth-quarter loss of $106.9 million last week due to a variety of charges associated with the merger of Applied Biosystems and Invitrogen last November that created the company.

Though the company's revenues fell short of analysts' expectations, the legacy Invitrogen business recorded organic revenue growth of 7 percent.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.